Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
Onco-Innovations Limited (CSE:ONCO) has announced the transfer of its common shares listing from the Canadian Securities Exchange (CSE) to Cboe Canada Inc. The transition will take effect on May 22, 2025, with the company maintaining its existing ticker symbol "ONCO". The voluntary delisting from CSE is scheduled for May 21, 2025.
Cboe Canada, a Tier 1 stock exchange within the global Cboe Markets network, provides advanced market infrastructure and real-time data solutions, including its ETF Market Canada platform that analyzes over 1,200 Canadian ETFs. CEO Thomas O'Shaughnessy emphasized that this strategic move aims to enhance the company's visibility in capital markets, broaden its investor base, and strengthen institutional engagement.
Onco-Innovations Limited (CSE:ONCO) ha annunciato il trasferimento della quotazione delle sue azioni ordinarie dalla Canadian Securities Exchange (CSE) a Cboe Canada Inc.. La transizione avverrà il 22 maggio 2025, mantenendo il simbolo ticker "ONCO". La cancellazione volontaria dalla CSE è prevista per il 21 maggio 2025.
Cboe Canada, una borsa di primo livello all'interno della rete globale di Cboe Markets, offre infrastrutture di mercato avanzate e soluzioni di dati in tempo reale, incluso il suo piattaforma ETF Market Canada che analizza oltre 1.200 ETF canadesi. Il CEO Thomas O'Shaughnessy ha sottolineato che questa mossa strategica mira a migliorare la visibilità dell'azienda nei mercati dei capitali, ampliare la base di investitori e rafforzare il coinvolgimento istituzionale.
Onco-Innovations Limited (CSE:ONCO) ha anunciado el traslado de la cotización de sus acciones comunes de la Canadian Securities Exchange (CSE) a Cboe Canada Inc.. La transición tendrá efecto el 22 de mayo de 2025, manteniendo el símbolo bursátil "ONCO". La exclusión voluntaria de la CSE está programada para el 21 de mayo de 2025.
Cboe Canada, una bolsa de nivel 1 dentro de la red global de Cboe Markets, ofrece infraestructura avanzada de mercado y soluciones de datos en tiempo real, incluyendo su plataforma ETF Market Canada que analiza más de 1,200 ETFs canadienses. El CEO Thomas O'Shaughnessy destacó que este movimiento estratégico busca mejorar la visibilidad de la empresa en los mercados de capital, ampliar su base de inversores y fortalecer el compromiso institucional.
Onco-Innovations Limited (CSE:ONCO)는 보통주 상장을 캐나다 증권 거래소(CSE)에서 Cboe Canada Inc.로 이전한다고 발표했습니다. 이 전환은 2025년 5월 22일에 시행되며, 회사는 기존의 티커 심볼 "ONCO"를 유지합니다. CSE에서의 자발적 상장 폐지는 2025년 5월 21일로 예정되어 있습니다.
Cboe Canada는 글로벌 Cboe Markets 네트워크 내의 1급 증권거래소로, 고급 시장 인프라와 실시간 데이터 솔루션을 제공하며, 1,200개 이상의 캐나다 ETF를 분석하는 ETF Market Canada 플랫폼을 운영하고 있습니다. CEO 토마스 오쇼네시는 이번 전략적 조치가 자본 시장에서 회사의 가시성을 높이고 투자자 기반을 확대하며 기관 투자자 참여를 강화하는 데 목적이 있다고 강조했습니다.
Onco-Innovations Limited (CSE:ONCO) a annoncé le transfert de la cotation de ses actions ordinaires de la Canadian Securities Exchange (CSE) à Cboe Canada Inc.. La transition prendra effet le 22 mai 2025, la société conservant son symbole boursier "ONCO". La radiation volontaire de la CSE est prévue pour le 21 mai 2025.
Cboe Canada, une bourse de niveau 1 au sein du réseau mondial Cboe Markets, offre une infrastructure de marché avancée et des solutions de données en temps réel, y compris sa plateforme ETF Market Canada qui analyse plus de 1 200 ETF canadiens. Le PDG Thomas O'Shaughnessy a souligné que ce mouvement stratégique vise à améliorer la visibilité de l'entreprise sur les marchés des capitaux, à élargir sa base d'investisseurs et à renforcer l'engagement institutionnel.
Onco-Innovations Limited (CSE:ONCO) hat den Wechsel der Notierung seiner Stammaktien von der Canadian Securities Exchange (CSE) zu Cboe Canada Inc. bekannt gegeben. Der Übergang wird am 22. Mai 2025 wirksam, wobei das Unternehmen sein bestehendes Tickersymbol "ONCO" beibehält. Die freiwillige Delistung von der CSE ist für den 21. Mai 2025 geplant.
Cboe Canada, eine Börse der Stufe 1 im globalen Cboe Markets-Netzwerk, bietet eine fortschrittliche Marktinfrastruktur und Echtzeit-Datenlösungen, darunter die ETF Market Canada-Plattform, die über 1.200 kanadische ETFs analysiert. CEO Thomas O'Shaughnessy betonte, dass dieser strategische Schritt darauf abzielt, die Sichtbarkeit des Unternehmens auf den Kapitalmärkten zu erhöhen, die Investorenbasis zu erweitern und die institutionelle Beteiligung zu stärken.
- None.
- None.
VANCOUVER, BC / ACCESS Newswire / May 16, 2025 / Onco-Innovations Limited (CSE:ONCO) ("Onco" or the "Company") is pleased to announce that it will transfer the listing of its common shares (the "Common Shares") to Cboe Canada Inc. ("Cboe Canada") from the Canadian Securities Exchange ("CSE"). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol "ONCO", and the Company has submitted a request to voluntarily delist its Common Shares from the CSE, which is expected to take effect at the close of trading on May 21, 2025. No action is required from shareholders regarding this transition.
Cboe Canada, a Tier 1 stock exchange and part of the global Cboe Markets network, offers a robust and internationally recognized platform for innovative companies seeking investor trust, liquidity, and visibility. Since launching in 2015, Cboe Canada has supported issuers through advanced market infrastructure and access to real-time data solutions, including its ETF Market Canada platform - an institutional-grade resource for exploring and analyzing over 1,200 Canadian ETFs. Real-time quotes and market information on Onco-Innovations can be found at www.cboe.com.
"Our move to Cboe Canada is a pivotal step in Onco-Innovations' journey as we scale our operations and deepen our commitment to developing impactful oncology solutions. This listing will not only enhance our visibility within the capital markets but also place us alongside a growing roster of forward-thinking companies focused on long-term value creation. We see this as an opportunity to broaden our investor base, strengthen engagement with institutions, and ensure that our capital strategy evolves in step with our scientific ambitions," stated Thomas O'Shaughnessy, CEO of the Company.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
Thomas O'Shaughnessy
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Cboe Canada have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the commencement of trading of the Common Shares on Cboe Canada, the Company's request to voluntarily delist the Common Shares from the CSE, and the Company's future goals and objectives. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain acts, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved".
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to transferring the Company's listing of its Common Shares from the CSE to Cboe Canada, the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all. Accordingly, readers should not place undue reliance on any such forward-looking information.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
When will Onco-Innovations (ONCO) start trading on Cboe Canada?
Why is Onco-Innovations moving from CSE to Cboe Canada?
Do Onco-Innovations shareholders need to take any action regarding the exchange transfer?
When will Onco-Innovations delist from the Canadian Securities Exchange (CSE)?
